Home page Home page

Adenuric
febuxostat

Package leaflet: Information for the user


ADENURIC 80 mg film-coated tablets ADENURIC 120 mg film-coated tablets Febuxostat


Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.



There have been rare reports of potentially life-threatening skin rashes (Stevens-Johnson Syndrome) with the use of ADENURIC, appearing initially as reddish target-like spots or circular patches often with central blister on the trunk. It may also include ulcers in the mouth, throat, nose, genitals and conjunctivitis (red and swollen eyes). The rash may progress to widespread blistering or peeling of the skin.

If you have developed Stevens-Johnson Syndrome with the use of febuxostat, you must not be re- started on ADENURIC at any time. If you develop a rash or these skin symptoms, seek immediate advice from a doctor and tell that you are taking this medicine.


If you are having a gout attack at the moment (a sudden onset of severe pain, tenderness, redness, warmth and swelling in a joint), wait for the gout attack to subside before first starting treatment with ADENURIC.


For some people, gout attacks may flare up when starting certain medicines that control uric acid levels. Not everyone gets flares, but you could get a flare-up even if you are taking ADENURIC, and especially during the first weeks or months of treatment. It is important to keep taking ADENURIC even if you have a flare, as ADENURIC is still working to lower uric acid. Over time, gout flares will occur less often and be less painful if you keep taking ADENURIC every day.


Your doctor will often prescribe other medicines, if they are needed, to help prevent or treat the symptoms of flares (such as pain and swelling in a joint).


In patients with very high urate levels (e.g. those undergoing cancer chemotherapy), treatment with uric acid-lowering medicines could lead to the build-up of xanthine in the urinary tract, with possible stones, even though this has not been observed in patients being treated with ADENURIC for Tumor Lysis Syndrome.


Your doctor may ask you to have blood tests to check that your liver is working normally.


Children and adolescents


Do not give this medicine to children under the age of 18 because the safety and efficacy have not been established.

Other medicines and ADENURIC


Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.

It is especially important to tell your doctor or pharmacist if you are taking medicines containing any

of the following substances as they may interact with ADENURIC and your doctor may wish to consider necessary measures:


Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.


  1. Contents of the pack and other information What ADENURIC contains

The active substance is febuxostat.

Each tablet contains 80 mg or 120 mg of febuxostat.


The other ingredients are:

Tablet core: lactose monohydrate, microcrystalline cellulose, magnesium stearate, hydroxypropylcellulose, croscarmellose sodium, colloidal hydrated silica.

Film-coating: Opadry II yellow, 85F42129 containing: polyvinyl alcohol, titanium dioxide (E171), macrogols 3350, talc, iron oxide yellow (E172)


What ADENURIC looks like and contents of the pack


ADENURIC film-coated tablets are pale yellow to yellow in colour and capsule shaped.

The 80 mg film-coated tablets are marked on one side with ‘80’ and on the other side with a score line. The 120 mg film-coated tablets are marked on one side with ‘120’.


ADENURIC 80 mg and 120 mg is packed in clear (Aclar/PVC/Aluminium or

PVC/PE/PVDC/Aluminium) blister of 14 tablets.


ADENURIC 80 mg and 120 mg is available in packs containing 14, 28, 42, 56, 84 and 98 film-coated tablets.


Not all pack sizes may be marketed.


Marketing Authorisation Holder and Manufacturer


Marketing Authorisation Holder

Menarini International Operations Luxembourg S.A. 1, Avenue de la Gare, L-1611 Luxembourg Luxembourg


Manufacturer Patheon France

40 boulevard de Champaret

38300 Bourgoin Jallieu France


or


Menarini - Von Heyden GmbH Leipziger Strasse 7-13

01097 Dresden

Germany


For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.


België/Belgique/Belgien Menarini Benelux NV/SA Tél/Tel: + 32 (0)2 721 4545

Lietuva

UAB “BERLIN-CHEMIE MENARINI

BALTIC”

Tel: +370 52 691 947


България

“Берлин-Хеми/А. Менарини България” EООД

тел.: +359 2 454 0950

Luxembourg/Luxemburg Menarini Benelux NV/SA Tél/Tel: + 32 (0)2 721 4545


Česká republika

Berlin-Chemie/A.Menarini Ceska republika s.r.o. Tel: +420 267 199 333

Magyarország

Berlin-Chemie/A. Menarini Kft. Tel.: +36 23501301


Danmark Pharmaprim AB Tlf: +468355933

Malta

Menarini International Operations Luxembourg S.A.

Tel: +352 264976

Deutschland

Berlin-Chemie AG

Tel: +49 (0) 30 67070

Nederland

Menarini Benelux NV/SA

Tel: +32 (0)2 721 4545


Eesti

OÜ Berlin-Chemie Menarini Eesti

Tel: +372 667 5001

Norge Pharmaprim AB Tlf: +468355933


Ελλάδα

MENARINI HELLAS AE

Τηλ: +30 210 8316111-13

Österreich

A. Menarini Pharma GmbH. Tel: +43 1 879 95 85-0


España

Laboratorios Menarini S.A.

Tel: +34-93 462 88 00

Polska

Berlin-Chemie/Menarini Polska Sp. z o.o.

Tel.: +48 22 566 21 00


France

MENARINI France

Tél: +33 (0)1 45 60 77 20

Portugal

A. Menarini Portugal – Farmacêutica, S.A. Tel: +351 210 935 500


Hrvatska

Berlin-Chemie Menarini Hrvatska d.o.o.

Tel : + 385 1 4821 361

România

Berlin-Chemie A.Menarini S.R.L.

Tel: +40 21 232 34 32


Ireland

A. Menarini Pharmaceuticals Ireland Ltd

Tel: +353 1 284 6744

Slovenija

Berlin-Chemie / A. Menarini Distribution

Ljubljana d.o.o.

Tel: +386 01 300 2160


Ísland Pharmaprim AB Sími: +468355933

Slovenská republika

Berlin-Chemie / A. Menarini Distribution

Slovakia s.r.o

Tel: +421 2 544 30 730


Italia

A. Menarini Industrie Farmaceutiche Riunite s.r.l.

Tel: +39-055 56801

Suomi/Finland

Berlin-Chemie/A.Menarini Suomi OY

Puh/Tel: +358 403 000 760


Κύπρος

MENARINI HELLAS AE

Τηλ: +30 210 8316111-13

Sverige Pharmaprim AB Tel: +468355933


Latvija

SIA Berlin-Chemie/Menarini Baltic

Tel: +371 67103210

United Kingdom (Northern Ireland)

A. Menarini Farmaceutica Internazionale S.R.L.

Tel: +44 (0)1628 856400


This leaflet was last revised in


.